Sandoz Launches Hyrimoz (biosimilar, adalimumab) in Canada

 Sandoz Launches Hyrimoz (biosimilar, adalimumab) in Canada

Shots:

  • The company expands its portfolio with the marketing of the 5th biosimilars in Canada. Hyrimoz is indicated for use in nine indications of the reference (Humira) in the field of rheumatology, gastroenterology and dermatology
  • Sandoz Canada has completed the pCPA negotiations for Hyrimoz, which is the first step in securing public reimbursement
  • Hyrimoz is a fully human TNF blocker and is available in 40 mg/0.8 mL & 20 mg/0.4mL in a prefilled syringe, 40 mg/0.8 mL in autoinjector in SensoReady Pen autoinjector designed for patients with limited dexterity

Click here ­to­ read full press release/ article | Ref: Sandoz | Image: Sandoz

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post